Gilead to acquire Tubulis for up to $5 billion to strengthen its oncology portfolio

The acquisition complements Gilead’s existing oncology expertise and development infrastructure

Insmed’s Brensocatib fails to hit endpoints in hidradenitis suppurativa study

The results were consistent across both the 10 mg and 40 mg treatment arms

Stereotaxis bags FDA clearance for next-gen cath lab tech

Asia emerges new hotspot for healthcare ransomware, says report

Cyble’s 2026 healthcare threat report flags a sharp rise in Asia-focused ransomware, with hospitals, elderly care, and diagnostic systems increasingly in cybercriminal crosshairs

Trialt and Viedoc team up to transform clinical trials

The partnership aims to accelerate clinical trial timelines, boost data quality, and improve decision-making for sponsors worldwide

Alpha Cognition secures key US patent for traumatic brain injury treatment

The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL

Regeneron and TriNetX forge $200M partnership to supercharge drug discovery and digital health

TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners

WHO updates global guidelines to combat opioid crisis

Opioid dependence remains a major driver of death and disease worldwide

KIMS Hospitals launches cutting-edge Neurosciences Institute in Mahadevapura

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion

The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio